WG
LRMR icon

Winton Group’s Larimar Therapeutics LRMR Stock Holding History

Winton Group’s Portfolio LRMR Stock Details LRMR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$160K Buy
+52,400
New +$208K 0.01% 1035
2020
Q2 		– Sell
-15,204
Closed -$140K – 1527
2020
Q1 		$140K Sell
15,204
-126
-0.8% -$1.66K ﹤0.01% 1295
2019
Q4 		$204K Buy
15,330
+2,010
+15% +$19.2K ﹤0.01% 1440
2019
Q3 		$118K Buy
+13,320
New +$146K ﹤0.01% 1451

Other funds holding LRMR

DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
BOCH
Blue Owl Capital Holdings New York $665M AUM 95.48% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DCM
Defilade Capital Management Emeryville, California $747M AUM
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
DCM
DAFNA Capital Management Los Angeles, California $524M AUM 164.42% 1-Year Est. Return

Winton Group's LRMR Position: Q2 2026 in Review

Winton Group opened a new position in Larimar Therapeutics (LRMR) in Q2 2026: 52,400 shares worth $160K. The stake represents 0.01% of the portfolio and ranks #1035 among its holdings. This is a return to the name: Winton Group previously reported a position in LRMR as recently as Q1 2020.

Winton Group first reported a position in LRMR in Q3 2019 and has held it in 4 quarters since. The position peaked at $204K in Q4 2019. 163 funds tracked by Wall St. Rank hold LRMR as of Q2 2026.

  • Winton Group held 52,400 shares of Larimar Therapeutics worth $160K as of Q2 2026.
  • Larimar Therapeutics was a new Winton Group position in Q2 2026.
  • Larimar Therapeutics made up 0.01% of Winton Group's portfolio in Q2 2026, its #1035 holding.
  • Winton Group first reported a position in Larimar Therapeutics in Q3 2019 and has held it in 4 quarters since.
  • Winton Group's Larimar Therapeutics position peaked at $204K in Q4 2019.
  • 163 funds tracked by Wall St. Rank held Larimar Therapeutics as of Q2 2026.

Based on Winton Group's 13F filing for Q2 2026, filed 7 Aug 2026.